Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 154 clinical trials
Venetoclax Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

  • 3 views
  • 26 Jan, 2021
  • 22 locations
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter

  • 0 views
  • 16 Mar, 2021
  • 20 locations
Rituximab Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell

cytarabine
renal function tests
cyclin d1
venetoclax
high dose chemotherapy
  • 14 views
  • 25 Mar, 2021
  • 49 locations
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore

romidepsin
mycosis
electron beam therapy
lymphoma
metastases
  • 3 views
  • 29 Jan, 2021
  • 1 location
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in

cytarabine
refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
cell transplantation
induction chemotherapy
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor

  • 0 views
  • 30 Jan, 2021
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

metastatic carcinoma
measurable disease
breast cancer
carcinoma
metastasis
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Study of Venetoclax a BCL2 Antagonist for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

  • 40 views
  • 16 May, 2021
  • 1 location
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of Ven-PegC in

  • 0 views
  • 21 May, 2021
  • 1 location
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML

  • 0 views
  • 07 Jun, 2021
  • 1 location